Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study.
RET fusion
RET inhibition
clinical trials
frontline therapy
lung
metastasis
non-small cell lung cancer
plain language summary
targeted therapy
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
This is a summary of a research study called ARROW, which tested a medicine called pralsetinib in patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumours caused by a change in a gene called In total, 281 patients with Overall, the ARROW study showed that pralsetinib was effective in shrinking tumours in patients with
Identifiants
pubmed: 37916501
doi: 10.2217/fon-2023-0155
doi:
Banques de données
ClinicalTrials.gov
['NCT03037385']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM